Medpace Holdings, Inc. (MEDP) Revenue CAGR:24.19%(TTM)
Revenue CAGR uses precomputed financial statement history.
Over longer horizons, Medpace Holdings, Inc.'s Revenue CAGR averages 19.66% over 3 years and 22.91% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how Medpace Holdings, Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
MEDP Revenue CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
MEDP Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.11B | $2.53B | +$421.18M | +19.97% | +19.97% |
| 2024 | $1.89B | $2.11B | +$223.21M | +11.84% | +11.84% |
| 2023 | $1.46B | $1.89B | +$425.85M | +29.17% | +29.17% |
| 2022 | $1.14B | $1.46B | +$317.62M | +27.80% | +27.80% |
| 2021 | $925.92M | $1.14B | +$216.45M | +23.38% | +23.38% |
| 2020 | $860.97M | $925.92M | +$64.96M | +7.54% | +7.54% |
| 2019 | $704.59M | $860.97M | +$156.38M | +22.19% | +22.19% |
| 2018 | $436.15M | $704.59M | +$268.44M | +61.55% | +61.55% |
| 2017 | $421.58M | $436.15M | +$14.57M | +3.46% | +3.46% |
| 2016 | $359.06M | $421.58M | +$62.52M | +17.41% | +17.41% |
| 2015 | $290.04M | $359.06M | +$69.02M | +23.80% | +23.80% |
| 2014 | $272.89M | $290.04M | +$17.15M | +6.28% | +6.28% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $706.60M | -0.3% | +26.5% |
| Q4 2025 | $708.45M | +7.4% | +32.0% |
| Q3 2025 | $659.90M | +9.4% | +23.7% |
| Q2 2025 | $603.31M | +8.0% | +14.2% |
| Q1 2025 | $558.57M | +4.1% | +9.3% |
| Q4 2024 | $536.59M | +0.6% | +7.7% |
| Q3 2024 | $533.32M | +1.0% | +8.3% |
| Q2 2024 | $528.10M | +3.3% | +14.6% |
| Q1 2024 | $511.04M | +2.5% | +17.7% |
| Q4 2023 | $498.40M | +1.2% | +26.5% |
| Q3 2023 | $492.50M | +6.9% | +28.3% |
| Q2 2023 | $460.87M | +6.2% | +31.2% |
| Q1 2023 | $434.07M | +10.1% | +31.2% |
| Q4 2022 | $394.10M | +2.7% | +27.7% |
| Q3 2022 | $383.74M | +9.3% | +29.8% |
| Q2 2022 | $351.21M | +6.1% | +26.2% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle